Excellerate Bioscience in successful EU consortium bid to develop new obesity therapeutics

Excellerate Bioscience has received a prestigious 1 million euro award from the Eurostars competition run by the EU intergovernmental innovation network EUREKA – in a consortium led by Atrogi AB, and also involving Stockholm and Maastricht universities, and the Latvian Institute of Organic synthesis.  The grant will combine Atrogi’s discoveries underpinning novel receptor therapeutics for obesity, with Excellerate’s international reputation in analytical receptor pharmacology and new assay paradigms for in vitro compound profiling.

Nick Holliday, Excellerate Bioscience CSO, commented: “Close collaboration with Atrogi AB and its partners has led to this outstanding success, with our project ranked 31 out of 449 EU wide applications.  We are excited that Excellerate’s expertise in the latest receptor pharmacology will now be able to contribute to an ambitious unique proposal to deliver new obesity treatments.”

“Obesity is a growing public health problem and finding new forms of treatment is extremely important to us from a societal perspective. We have high hopes for this groundbreaking project that is being implemented with distinguished researchers from top-tier European universities, institutes and Excellerate Bioscience,” said Alexandra Ekman Ryding, CEO of Atrogi AB.

The project begins in September 2020.